How The Hemangeol Deal Is Reframing The Eton Pharmaceuticals (ETON) Investment Story [Yahoo! Finance]
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Price targets on Eton Pharmaceuticals have been adjusted at the margins, with one bullish analyst moving from US$29 to US$30 while model fair value stays at US$39.33. That modest change is tied directly to commentary around the Hemangeol acquisition, where analysts weigh its US$12m in expected 2025 U.S. sales against execution risk and Eton's past licensing experience with Increlex. As you read on, you will see how these pieces fit together and what to watch to keep up with the evolving analyst narrative. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Eton Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Craig-Hallum raised its Eton Pharmaceuticals price target to US$30 from US$29 after the Hemangeol deal and describes the acquisition of U.S. rights as an attractive, near term accretive addition. Analysts highlight Hemangeol as the only FDA approved treatment for infantile hemangioma
Show less
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- Eton Pharmaceuticals Announces CFO Succession PlanGlobeNewswire
- How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals (ETON) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by HC Wainwright from $37.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals (ETON) had its price target raised by B. Riley Financial, Inc. from $26.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
ETON
Earnings
- 3/19/26 - Beat
ETON
Sec Filings
- 4/16/26 - Form 8-K
- 4/15/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- ETON's page on the SEC website